Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ALLR · NASDAQ · Pharmaceutical Preparations
Allarity Therapeutics (ALLR) · oqro.io/stocks/ALLR · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.865−0.007 (−0.80%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
No open-market purchase by an insider of Allarity Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Allarity Therapeutics (ALLR) was filed with the SEC in the last 90 days.
No trade in Allarity Therapeutics (ALLR) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−19.2% (−$0.205) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.07 on Nov 19, 2025 to $0.865 on Nov 19, 2026 (−19.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Boston, Ma.
Last 12 months
−19.2%
Market value
$13.8M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 231K shares sold short (1.4% of shares outstanding), +37.3% vs the previous count, 1.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$320K
Year ended Dec 31, 2025
Net income, fiscal 2025
−$11.2M
A loss for the year
Shares outstanding
16M
As of Nov 12, 2026
In fiscal 2025 the company spent $3.19M buying back its own shares. Cash actually paid, from its cash-flow statement.
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 18, 2025, ALLR is down 24.1% and the index fund is up 8.5%: 33 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ALLR moves
Beta 1.2 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in advanced ovarian cancer. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
No Schedule 13D or 13G filing on ALLR over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Revenue
$5K
Year earlier: $0
Free cash flow, last 12 months
−$13.2M
This quarter −$2.88M, a year earlier −$3.41M
Net debt
—
Debt —, cash $14.1M, at Sep 30, 2026
Net income, last 12 months
−$15.7M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 14, 2026.
Revenue and earnings history, 6 fiscal yearsEarnings dates and the stock's moves
Latest annual report filed Mar 30, 2026, compared with the one filed Mar 31, 2025. Read the filing
All 78 risk factor headings match the year before, give or take wording.
For information regarding our material legal proceedings, see “Note 14. Commitments and Contingencies” in the accompanying “Notes to Consolidated Financial Statements” in this Annual Report, which information is incorporated herein by reference.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
· Administrative proceeding · 33-11367
Biopharmaceutical Company Settles Charges for Disclosure FailuresThe SEC wrote: The Securities and Exchange Commission today announced settled charges against Massachusetts-based biopharmaceutical company Allarity Therapeutics, Inc. for disclosure failures through the conduct of certain former officers that concealed from the public a harsh critique levied by the Food and Drug Administration (FDA) in February 2020 about the likelihood that dovitinib, Allarity's flagship cancer drug candidate,…
The SEC says the respondent agreed to settle without admitting or denying the allegations or findings.
These are SEC announcements. Charges in a complaint or an order instituting proceedings are allegations; quoted text is the SEC's own wording. Listed when the company is named as a respondent under its exact legal name, or by the CIK or ticker the SEC states. Actions against subsidiaries or former names are not listed. Source: SEC.gov litigation releases, administrative proceedings and trading suspensions, checked Nov 19, 2026.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell’s sensitivity to a specific cancer therapeutic. Once defined, the DRP® gene expression signature can then be assessed in cancer tissue biopsies from patients to identify those cancers that share this signature of drug sensitivity, and by extension, to identify those patients who may then be most likely to receive benefit from that specific anti-cancer therapeutic.
And 19 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 55.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (5.5% on ATS, 49.7% with other brokers), below its 26-week average of 59.9%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (27.8%), UBS ATS (14.3%), VIRTU MATCHIT ATS (10.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.